Stable Gastric PentadecapeptideBPC 157, Somatosensory Neurons and Their Protection and Therapeutic Extensions — A Survey

  title={Stable Gastric PentadecapeptideBPC 157, Somatosensory Neurons and Their Protection and Therapeutic Extensions — A Survey},
  author={Predrag Sikiric},
Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M. W. 1419, a partial sequence of human gastric juice protein BPC, in all studies used peptide with 99% (HPLC) purity, freely soluble in water at pH 7. 0 and in saline), was always given alone, without any carrier, μg-ng dose ranges and ways of application, intraperitoneal, intragastrical, in drinking water or topically, at the site of injury. Besides, tested in therapy of inflammatory bowel disease (IBD) (PL 14736) in clinical phase II… 

Tables from this paper



Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.

In rat esophagitis and failed function of both lower esophageal sphincter (LES) and pyloricSphincters (PS), BPC 157 increased pressure in both spHincters till normal and reduced esophAGitis, and may improve gastrointestinal tract therapy.

Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157.

Supporting evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis.

Stable gastric pentadecapeptide BPC 157-NO-system relation.

Stable gastric pentadecapeptide BPC 157-NO-system-relation is reviewed, its close participation in Moncada's (maintained vascular integrity, platelets control) homeostatic healing response of NO-system to injury and how this advantage of modulating NO- system may be practically translated into an enhanced clinical performance remains to be determined.

Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157.

Beneficial and counteracting effects of BPC 157 were obtained using the equipotent dosage in parenteral or peroral regimens, unlike the different dosage levels of aspirin, as a NSAIDs prototype, which differ by a factor of about ten.

Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability.

  • R. KlicekD. Kolenc P. Sikiric
  • Medicine, Biology
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • 2013
BPC 157-cuprizone rats had consistently less nerve damage in all damaged areas, especially in those areas that otherwise were most affected, and this experimental evidence advocates BPC 157 in both inflammatory bowel disease and multiple sclerosis therapy.

Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.

BPC 157 accelerated parenterally or perorally the healing of colonic and skin defect, leading to the suitable closure of the fistula, macro/microscopically, biomechanically, and functionally (larger water volume sustained without fistula leaking).

Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats.

The effect of pentadecapeptide BPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity

The anti-nociceptive effects of a newly synthesized pentadecapeptide coded BPC 157 (an essential fragment of new organoprotective gastric juice peptide BPC) was evaluated in comparison with aspirin

Traumatic brain injury in mice and pentadecapeptide BPC 157 effect